Skip to content

Epilepsy-Associated Stigma

EPILEPSY-ASSOCIATED STIGMA AND ILLNESS EXPERIENCE IN PEOPLE WITH EPILEPSY

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01374204
Acronym
EPISTIGMA
Enrollment
200
Registered
2011-06-15
Start date
2011-07-31
Completion date
2019-06-30
Last updated
2019-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

Epilepsy, Stigma

Brief summary

Few data about epilepsy-associated stigma in France are available. The only study we have found showed that in France 66% of people with epilepsy felt stigmatized by their condition and are often single, compared with the other European patients interviewed (Baker et al., 2000). The purpose of this study is to assess the association between type of epilepsy (drug resistant-epilepsy and stabilized epilepsy) and perceived stigma (using the Stigma Scale) in patients recruited in the Limousin region .

Detailed description

Epilepsy-associated stigma leads important problems in terms of public health because it can provoke significant cognitive repercussions, impairment of quality of life and it causes physical injuries and serious disabilities. These social consequences often cause more suffering for patients than seizures themselves. This heavy medical and social burden is associated with significant economic cost in terms of care and disability. It is also noted that mortality rate is 2 to 10 times higher than the general population. It is therefore urgent to consider both medical and social dimension of consequences of epilepsy especially in patients with uncontrolled seizures. It is also essential to detect a potential psychiatric disorder associated with epilepsy, especially depression and anxiety which are the most prevalent psychiatric comorbidities. These disorders are often under-diagnosed that can frequently leads to an inappropriate care. The purpose of this study is to assess the association between type of epilepsy (drug resistant-epilepsy and stabilized epilepsy) and perceived stigma (using the Stigma Scale) in patients recruited in the Limousin region . The primary outcome will be the score of perceived stigma obtained from the Stigma Scale. This scale estimates a score of perceived stigma for each individual and allows classifying individuals in 3 categories. Thus, individuals who obtain a total score of 0 will be those who do not feel stigmatized. Those whose scores will be over or equal to 1will be those who feel stigmatized. Finally, respondents whose the score is equal to 3 will be considered as having a strong perception of stigma. A positive response is characterized by threshold ≥ 1.

Interventions

None listed

Sponsors

University Hospital, Limoges
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years and above * diagnosed by a neurologist as suffering from drug-resistant epilepsy (all types of seizures) outpatient in Neurology service of the investigation centres * inhabitant in the Limousin region * having signed the informed consent * affiliated or profiting of a social security system

Exclusion criteria

* patients that are deprived of their freedom * patients with disabilities * patients suffering from a chronic or an acute delusional disorder * patients suffering from others handicaps

Design outcomes

Primary

MeasureTime frameDescription
score of perceived stigmaDay oneThis scale estimates a score of perceived stigma for each individual and allows classifying individuals in 3 categories. Thus, individuals who obtain a total score of 0 will be those who do not feel stigmatized. Those whose scores will be over or equal to 1will be those who feel stigmatized. Finally, respondents whose the score is equal to 3 will be considered as having a strong perception of stigma. A positive response is characterized by threshold ≥ 1.

Secondary

MeasureTime frame
Evaluation of the illness experience will be performed by the first section of the EMIC.
Evaluation of the representations of epilepsy (perceived causes) will be done by the second section of the EMIC

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026